Back to first-pass browser

First-pass extracted concept

in vivo CAR-T cell therapy

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

in vivo CAR T cell therapy

Extracted Explainers

What the tool is doing

This strategy genetically modifies T cells to express CAR protein directly in the body by delivery of vectors. It is presented as an alternative to conventional ex vivo CAR-T manufacturing.

Source 1DOIPubMed

Resources required

The abstract states that vectors are used to deliver CAR-encoding material in vivo. It also indicates dependence on optimized gene delivery systems, gene editing technologies, and CAR structures.

Source 1DOIPubMed

What problem it solves

It aims to address manufacturing complexity, high cost, and the time-consuming nature of standard CAR-T cell production. The review frames it as a way to improve anti-tumor effectiveness and safety.

Source 1DOIPubMed

What it does not solve

The abstract explicitly notes unresolved challenges including delivery safety, CAR-T persistence and function, and the immunosuppressive microenvironment in solid tumors.

Source 1DOIPubMed

Alternatives

The implied alternative is conventional ex vivo CAR-T cell immunotherapy, which requires manufacturing cells outside the body before administration.

Source 1DOIPubMed

Evidence Snippets

In recent years, the strategy of in vivo CAR-T cell therapy is emerging as a promising approach to improve anti-tumor effectiveness and safety.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1approach promisesupports2025Source 1DOIPubMed

In vivo CAR-T cell therapy is emerging as a promising approach to improve anti-tumor effectiveness and safety.

Quoted textsource-backed
In recent years, the strategy of in vivo CAR-T cell therapy is emerging as a promising approach to improve anti-tumor effectiveness and safety.
Claim 2challenge statementsupports2025Source 1DOIPubMed

Key challenges for in vivo CAR-T cell therapy include gene-delivery safety, CAR-T cell persistence and function, and the immunosuppressive microenvironment in solid tumors.

Quoted textsource-backed
We discuss the challenges of in vivo CAR-T cell therapy, such as safety issues of gene delivery, the persistence and function of CAR-T cell, and the immunosuppressive microenvironment in solid tumors.
Claim 3field progresssupports2025Source 1DOIPubMed

Optimization of gene delivery systems, gene editing technologies, and CAR structures has enhanced the safety, effectiveness, and clinical application of in vivo CAR-T therapies.

Quoted textsource-backed
With the continuous optimization of gene delivery systems, gene editing technologies and CAR structures, advancements in in vivo CAR-T therapies have notably enhanced safety, effectiveness, and application in clinical settings.
Claim 4mechanism descriptionsupports2025Source 1DOIPubMed

In vivo CAR-T cell therapy genetically modifies T cells to express CAR protein directly in the body by delivery of vectors.

Quoted textsource-backed
Briefly, T cells are genetically modified to express CAR protein directly in the body by delivery of vectors.
Claim 5problem statementsupports2025Source 1DOIPubMed

Conventional CAR-T cell immunotherapy faces manufacturing complexity, high cost, and a time-consuming process.

Quoted textsource-backed
Chimeric antigen receptor (CAR)-T cell immunotherapy represents an evolutionary advance in the treatment of cancer, yet it faces challenges such as manufacturing complexity, high cost, and time-consuming process.